Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Ascelia Pharma AB logo — Ascelia Pharma is an oncology-dedicated orphan drug company...

Ascelia Pharma AB

Ascelia Pharma is an oncology-dedicated orphan drug company listed on Nasdaq Stockholm under the ticker ACE.

Founded 2000 Sweden Sweden 16 employees Post-IPO Equity Total: $200.00M Biotechnology, Health Care +1

General Information

Company Name Ascelia Pharma AB
Founded Year 2000
Location Sweden Sweden
Employees 16
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Ascelia Pharma AB. To contact Ascelia Pharma AB, visit ascelia.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Ascelia Pharma AB compare?

A PDF of Ascelia Pharma AB and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Ascelia Pharma AB soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Ascelia Pharma AB

Ascelia Pharma AB is a biotech company based in Sweden, specializing in orphan oncology treatments. The company is listed on Nasdaq Stockholm under the ticker ACE. As of March 17, 2021, it received a kr200.00MPost-IPO Equity investment from notable investors including Sunstone Capital, HealthInvest Partners, Oresund Healthcare Management, Fourth Swedish National Pension Fund, and Svenska Handelsbanken. Ascelia Pharma has two promising drug candidates in its pipeline. The first is Orviglance (formerly known as Mangoral), a novel oral contrast agent for MR-imaging designed to enhance the detection of focal liver lesions in patients with reduced kidney function. This drug has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA) and is currently in Phase 3 development, including the global multi-center SPARKLE study. The second candidate is Oncoral, a novel oral irinotecan tablet developed for the treatment of difficult-to-treat cancers, initially focusing on gastric cancer. This drug has shown promising results in Phase 1 clinical trials, and Phase 2 development is in preparation. Overall, Ascelia Pharma's innovative approach to addressing unmet medical needs in the oncology space, along with its strong investor support, positions the company as a significant player in the biotechnology and pharmaceutical industries.

Business keywords: biotech, oncology, orphan drug, MRI contrast agent, liver lesions, chemotherapy, gastric cancer, pharmaceutical, clinical development, FDA orphan drug designation, irinotecan, drug development, global headquarters, Nasdaq Stockholm, Malmö, Sweden

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity kr200.00M 5
Sunstone Capital HealthInvest Partners Oresund Healthcare Management
Sunstone Capital, HealthInvest Partners +3
17 Mar 2021

Ascelia Pharma AB Alternatives & Competitors

View All Alternatives
Ascelia Pharma AB vs
SciTech Development, Inc.
SciTech Development, Inc. United States

SciTech Development is a Specialty Pharmaceutical Company dedicated to advancing breakthrough cancer...

Venture round
8 employees
Biotechnology, Life Sciences
Ascelia Pharma AB vs
Medivir AB
Medivir AB Sweden

Improving life for cancer patients through transformative drugs

Post-IPO Equity
46 employees
Biotechnology, Pharmaceutical
Ascelia Pharma AB vs
Vicore Pharma AB
Vicore Pharma AB Sweden

Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class...

Post-IPO Equity
41 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Ascelia Pharma AB

Ascelia Pharma is an oncology-dedicated orphan drug company listed on Nasdaq Stockholm under the ticker ACE.
Ascelia Pharma AB was founded in 2000.
Ascelia Pharma AB is headquartered in Sweden.
Ascelia Pharma AB operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on biotech, oncology, orphan drug and MRI contrast agent.
Ascelia Pharma AB has approximately 16 employees.
Ascelia Pharma AB has completed 1 funding round, raising a total of $200.00M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Ascelia Pharma AB include SciTech Development, Inc., Medivir AB, Vicore Pharma AB, Quince Therapeutics, Versantis. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Ascelia Pharma AB and SciTech Development, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Ascelia Pharma AB, https://bouncewatch.com/company/ascelia-pharma-ab, updated 17 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes